Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Palo (Details)

v3.22.2
Royalty and Commercial Payment Purchase Agreements - Palo (Details)
$ in Thousands
6 Months Ended 12 Months Ended
Sep. 26, 2019
USD ($)
item
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Agreements        
Payments related to purchase of royalty rights and other commercial payment rights     $ 13,500  
Long-term royalty and commercial payment receivables   $ 66,575   $ 69,075
Impairment of long-term royalty receivable   0   0
Palo | Royalty Purchase Agreement        
Agreements        
Number of drug candidates | item 6      
Payments related to purchase of royalty rights and other commercial payment rights $ 10,000      
Long-term royalty and commercial payment receivables $ 10,000      
Impairment of long-term royalty receivable   $ 0   $ 0